August 8, 2014 / 1:32 PM / in 3 years

BUZZ-Biocryst Pharmaceuticals Inc: Ebola outbreak garners interest

** Drug developer’s shares up 3.8 pct at $13.40 premarket

** Ebola outbreak has significantly increased visibility Biocryst’s experimental broad spectrum antiviral, BCX4430

** Although current focus for BCX4430 is against Marburg virus, we see future development against Ebola - Brinson Patrick analyst Christopher James

** With ongoing Ebola outbreak garnering interest in BCX4430’s further study, we believe government-driven stockpiling market opportunity is emerging - MLV & Co analyst Vernon Bernardino

** Canadian drugmaker Tekmira Pharmaceuticals Corp’s U.S.-listed shares up 18.5 pct premarket

** FDA said Thursday it modified clinical hold on Tekmira’s experimental Ebola drug from “full” to “partial” to enable potential use in people infected with the virus

** Sarepta Therapeutics Inc shares up 3 pct, NanoViricides Inc up 9 pct premarket; Both companies developing ebola treatments

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below